Routine cognitive screening in Parkinson disease (PD) has become essential for management, to track progression and to assess clinical status in therapeutic trials. Patients with mild cognitive impairment (PD-MCI) are more likely to progress to dementia and therefore need to be distinguished from patients with normal cognition and those with dementia. A three-class Youden index has been recentl...
